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Abstract
Background: While mortality in the United States has decreased for most cancers, mortality from combined
hepatocellular liver cancer and intrahepatic cholangiocarcinoma (ICC) has increased and ranked 1st in annual
percent increase among cancer sites. Because reported statistics combine ICC with other liver cancers, mortality
rates of cholangiocarcinoma (CCA) remain unknown. This study is to determine CCA mortality trends and variation
based on national data.
Methods: This nation-wide study was based on the underlying cause of death data collected by the National Center
for Health Statistics (NCHS) between 1999 and 2014. The Center for Disease Control (CDC) Wide-ranging Online Data
for Epidemiologic Research (WONDER) system was used to obtain data. ICC and extra-hepatic CCA (ECC) were
defined by ICD-10 diagnosis codes. Age-adjusted mortality rate was standardized to the US population in 2000.
Results: There were more than 7000 CCA deaths each year in the US after 2013. CCA mortality for those
aged 25+ increased 36 % between 1999 and 2014, from 2.2 per 100,000 (95 % confidence interval [CI] 2.1–2.3)
to 3.0 per 100,000 (95 % CI, 2.9–3.1). Mortality rates were lower among females compared with males (risk
ratio [RR] 0.78, 95 % CI 0.77–0.79). Asians had the highest mortality. Between 2004 and 2014, the increase in
CCA mortality was highest among African Americans (45 %) followed by Asians (22 %), and whites (20 %).
Conclusion: Based on the most recent national data, CCA mortality rates have increased substantially in the past
decade. Among different race/ethnic groups, African Americans have the highest increase in CCA mortality.
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Study highlights
What is current knowledge
While research has begun to focus on the increasing in-
cidence of intrahepatic cholangiocarcinoma (ICC) as a
distinct entity from hepatocellular carcinoma, the overall
mortality from cholangiocarcinoma (CCA) in the United
States beyond 2005 has not been reported.
What is new here
Our study of the National Center for Health Statistics dem-
onstrates that the death toll due to CCA rose substantially
in the past decade in the US and has exceeded 7000 annu-
ally, which is more than double the widely-quoted Ameri-
can Cancer Society estimate of 2000–3000 new cases of
CCA per year. Among different race/ethnic groups, African
Americans have the highest increase in CCA mortality.
Background
Cholangiocarcinoma (CCA), also known as bile duct
cancer, is a rare cancer originating from the epithelial
cells of the biliary ducts [1]. CCA can occur anywhere
along this tract from the ampulla of Vater to the
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intrahepatic biliary radicals. The hepatic duct bifurcation
is historically reported to be the most frequently in-
volved site; the extrahepatic cholangiocarcinoma (ECC)
tumors at this particular location are called Klatskin tu-
mors [2]. If CCA occurs within the intrahepatic biliary
radicals, it is termed intrahepatic cholangiocarcinoma
(ICC). Clinical presentation is variable and dependent
on the location of the primary tumor, and it is rare for
symptoms to manifest early in the course of the disease
[3].
Risk factors for CCA include primary sclerosing chol-
angitis, bile duct stones, liver fluke infection, biliary-duct
cysts, hepatolithiasis, inflammatory bowel disease (IBD),
hepatitis C, Hepatitis B, cirrhosis, obesity, diabetes, alco-
hol, smoking, and genetic polymorphisms [4–7], all asso-
ciated with inflammation [6, 8]. CCA is associated with
high mortality. The median overall survival is 20–28
months and 5-year survival rates are about 25 % [9, 10].
Given the rising incidence and high mortality, a better
understanding of the populations at risk for mortality
from CCA is warranted.
Historically, the Surveillance Epidemiology, and End
Result (SEER) classification system placed ICC in the
same category as primary liver cancer of hepatocyte ori-
gin, hepatocellular cancer (HCC) [4]; however, given the
neoplastic origin of ICC in the biliary ducts, it should be
studied together with ECC for purposes of understand-
ing risk factors or mortality. Accordingly, the term CCA
is now used for all primary tumors of the bile ducts [11].
Because the SEER database combined ICC with HCC
[4], and because ECC has historically been reported sep-
arately, comprehensive national mortality rates of CCA
are not previously well-characterized. While cancer mor-
tality decreased in the US overall by 1.5 % per year dur-
ing 2008–2012 [12], during the same period the
mortality rate from cancers of the liver (HCC and ICC)
increased by 3.3 % per year [12]. The relative change
was the highest found among the 19 cancer sites tracked
[12]. However, these results do not tell us if the steep in-
crease arose from changes in HCC, ICC, or both.
Existing reports documented 300–400 % increases in
CCA mortality rates in the US between 1975 and 1997
[13]. A study specifically of ICC published in 2014 found
that the incidence of ICC in the US had increased be-
tween 1973 and 2010 [14], but did not include ECCs
[14]. Although a recent study has examined incidence of
both ICC and ECC in the SEER database [15], CCA
mortality for the entire US population beyond 2004 has
not been studied; therefore it has not been shown if
CCA mortality continues to rise. To provide contempor-
ary insight into CCA mortality rates, we undertook a
national study based on ICD-10 cause of death, the
first classification scheme to provide distinct codes
for intra-hepatic CCA (ICC) and extra-hepatic CCA
(ECC), thus allowing calculation of overall CCA mor-
tality. Using this data, we sought to examine CCA
mortality over time and to assess the effects of age,
gender, and race or ethnicity.
Methods
Data sources
The data for this study came from the underlying cause
of death data collected by the National Center for Health
Statistics (NCHS), which comprises data for the entire
US population. Data for US residents over age 25 were
extracted from the Centers for Disease Control (CDC)
Wide-ranging Online Data for Epidemiologic Research
(WONDER) system to describe the CCA mortality rates
between 1999 and 2014. Data for the population under
age 25 were unreliable due to the small number of
events and therefore were excluded from the analysis.
ICC was defined by ICD-10 code C22.1 (Intrahepatic
bile duct neoplasms) and ECC was defined by ICD-10
codes, C24.0 (extra-hepatic bile duct neoplasms), C24.8
(Overlapping lesion of biliary tract neoplasm), and C24.9
(biliary tract, unspecified neoplasms). Informed consent
was waived as the raw data are publicly available via
CDC WONDER. The codes used to identify ICC and
ECC are provided in the method section.
Statistical analyses
This study aims to provide CCA mortality rates over
time and examine how the rates vary with age, gender,
and race. For the time trend analysis (Fig. 1), age-
adjusted rates were standardized to US 2000 population
using the direct method [16]. The effects of ethnicity/
race and gender were derived from Mantel-Haenszel es-
timates adjusting for age [16]. STATA v.14 (Stata Corp.
2015. version 14. College Station, TX) was used to con-
duct the analyses.
Results
This study included 85,248 deaths due to cholangiocarci-
noma (CCA). The majority of patients died at age 55 or
older (Table 1). The number of CCA deaths increased
substantially over time (Fig. 1), from 3889 in 1999 to
7224 in 2014. The age-adjusted CCA mortality rates in-
creased from 2.2 per 100,000 (95 % confidence interval
(CI), 2.1–2.3) in 1999 to 3.0 per 100,000 (95 % CI,
2.9–3.1) in 2014. As can be seen in Fig. 1, approxi-
mately two-thirds of CCA mortality were from ICC
morality, which increased steadily over time; in con-
trast, ECC mortality stayed relatively stable during the
study period.
CCA mortality increased with age and has done so
even as overall mortality increased. Rates were low for
those aged <55 years but increased substantially there-
after, reaching 15.1 (95 % CI 14.7–15.4) per 100,000
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among females aged 85+ and 20.0 (95 % CI 19.4–20.6)
per 100,000 for males aged 85+ (Fig. 2). In addition to
age, gender is an important predictor of CCA mortality:
females were at lower risk than males (rate ratio 0.78,
95 % 0.77–0.79).
Rate of cholangiocarcinoma mortality decreased among
Native Americans but increased in Asians, Whites, and
African Americans between 2004 and 2014. The increase
in CCA mortality was highest among African Americans
(45 %) followed by Asians (22 %), and whites (20 %) (Fig. 3).
Asians were at highest risk of mortality among all
races for both men and women. Figure 4 shows that
the increase in CCA mortality was 18 % among His-
panics and 38 % among non-Hispanics between 2004
and 2014.
Discussion
Previous literature is sparse and not conclusive regarding
the combined mortality from ICC and ECC. The current
study uniquely examines combined ICC and ECC mor-
tality as a group based on the latest national data, and
shows a consistent increase in CCA mortality across age
and gender since 1999. In our analysis, the increasing
trend concentrated in ICC, not ECC. Our study showed
that the number of CCA deaths has increased substan-
tially since 1999, reaching over 7000 cases a year in
2013. The majority of patients with CCA develop a re-
currence after resection [17], and there is considerable
perioperative mortality [18]; therefore, mortality from
this disease is a strong indicator of incidence. Our data
suggest that the widely quoted rate of 2000–3000 new
cases of CCA per year is an under-estimate [19–23], and
that there has been a true increase in incidence of CCA.
Our results parallel a recent study of data up to 2009 in
the 33 Cancer Registries that participate in the North
American Association of Central Cancer Registries [12]
and are consistent with a trend demonstrated in the
Fig. 1 Cholangiocarcinoma mortality for those aged 25+ increased 36 % between 1999 and 2014, from 2.2 per 100,000 (95 % confidence interval
[CI] 21-2.3) to 3.0 per 100,000 (95 % CI, 2.9–3.1). Most of the increase resulted from increased intrahepatic cholangiocarcinoma mortality
Table 1 Characteristics of patients who died of
Cholangiocarcinoma in 1999–2014
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Asian or Pacific Islander 4017 4.7
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incidence of CCA among the SEER population up to 2012
[15], but are derived from more complete national data.
We observed significant variations in CCA mortality
across race and gender after adjusting for age distribu-
tions. Of particular note, increased risk was associated
with male gender overall, Asian ethnicity for both gen-
ders, Hispanic women, and advanced age. Notably, while
the risk of dying of all cancers combined is highest
among African Americans [24], we found that risk of
CCA mortality was lower, although increasing, among
African Americans compared to other ethnic groups.
The NCHS mortality database does not include data on
potential risk factors of CCA such as primary sclerosing
cholangitis (PSC), so we cannot quantify the contribution
of various risk factors on CCA mortality. However, exter-
nal data sources show that the higher risk of CCA mortal-
ity in males is likely to be related to increased risk in
hepatitis C, cirrhosis and PSC. Epidemiological studies
have found that risk of CCA increases 27-fold with cirrho-
sis (adjusted odds ratio, 27.2; P <.0001) [25], six-fold with
hepatitis C virus infection, (adjusted odds ratio, 6.1; P
<.0001) [25, 26], and 1560 times with PSC (HR 1560; 95 %
CI = 780, 2793; p <0.0001) [27]. Furthermore, compared
with females, males have higher risk of hepatitis C (176 vs.
105 per 100,000) [28], chronic liver disease (305 vs 206
per 100,000) [28], and PSC (0.45 vs. 0.37 per 100,000)
[29]. The higher risk of CCA mortality among males in
our study may be related in part to the fact that men are
Fig. 2 Cholangiocarcinoma mortality increases with age; the risk is higher among males than females. Adjusted risk ratio of females to males is
0.78 (95 % CI 0.77–0.79)
Fig. 3 Rate of cholangiocarcinoma mortality decreased among Native Americans but increased in Asians, Whites, and African Americans between
2004 and 2014. The increase in CCA mortality was highest among African Americans (45 %) followed by Asians (22 %) and whites (20 %)
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at higher risk for both cirrhosis and PSC [6]. PSC is, how-
ever, is a rare diagnosis affecting at most 16.2 per 100,000
people in some studies.
Extensive evidence implicates inflammation and
cholestasis as key factors in the pathogenesis of CCA
[8, 30, 31]. Inflammatory markers are also universally
elevated in metabolic syndrome [32]. In the face of
the increasing burden of CCA we have demonstrated and
given the increasing incidence of the metabolic syndrome
in the United States [33], a recent large study examining
preexisting metabolic syndrome as a risk factor for pri-
mary liver tumors (not differentiating between ICC and
HCC) bears attention [34]. In addition, obesity itself is be-
coming established as an independent risk factor for CCA
[35]. While there are multiple mechanisms by which the
metabolic syndrome may be linked to the pathogenesis of
gastrointestinal malignancies [36], a putative etiologic link
between obesity and CCA is leptin, the hormone regulat-
ing homoeostasis which is increased in obese patients, and
has been shown to stimulate grown, migration and pre-
vent apoptosis of a CCA cell model [37]. Thus, the under-
lying etiology of this increase in ICC across gender and
race may possibly be related to the prevalence of meta-
bolic syndrome and obesity [34, 35, 37, 38].
In addition to inflammatory risk factors that may cross
ethnicities, there are well-established risk factors for
CCA specific to ethnicities that merit notice given the
significant racial and ethnic variations in CCA mortality
in our study. The high risk of CCA mortality among
Asians is unsurprising as CCA is more common in
Southeast Asia [39, 40], potentially because of the preva-
lence of infections such hepatitis B and C virus [41], and
hepatobiliary fluke infection, prevalent in Asia [42], both
inflammatory [43] risk factors for CCA [3, 8, 44–46]. In
addition, hepatolithiasis is more commonly noted in
Asia than in Western countries and is associated with a
10 % incidence of CCA [8, 47–49]. Another potential
contributing factor to the increased incidence among
Asians is Type 2 diabetes mellitus (T2DM) [46]. Dia-
betes has been associated with CCA in a Taiwanese
population for both ICC (OR = 2.0) and ECC (OR = 1.8)
[46]. The mortality and incidence rate from T2DM in-
creased more in Asians than in their Caucasian or Afri-
can American counterparts [50], despite on average a
substantially lower BMI in the Asian population [51].
African Americans have 2.6 times the mortality due to
diabetes compared with those of Asian descent [50], and
although the mortality and incidence rates for most
other cancers are higher for African Americans [24, 52],
and African Americans have the highest increase in
CCA mortality, they have substantially lower overall risk
of CCA mortality in our study and in the earlier study of
ICC [53]. That study also found that although hepato-
biliary cancers were highly prevalent in Asian Pacific Is-
landers, the prevalence of ICC was not significantly
different from that of other racial groups [53]. Those re-
sults, in combination with the data we present here, sug-
gest that the increased mortality in Asians in the United
States may be due to ECCs.
Another notable finding in our study was that the
rate of death from CCA increased substantially with
age (Fig. 2). This finding is consistent with the trend
observed in the SEER databases for HCC, which
notes that among persons 75 to 84 years, increases in
HCC incidence were seen among all men and white
women (P ≤0.05) in the United States from 1975 to
Fig. 4 Cholangiocarcinoma mortality increased in both Hispanic and non-Hispanic populations. Between 2004 and 2014, the increase in CCA mor-
tality was 18 % among Hispanics and 38 % among non-Hispanics
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2005 [54]. Given that some authors have found de-
creased mortality from ICC, and have attibuted the
decrease to better detection [14], the increase in CCA
mortality with age may be in part related to surgical
mortality. The incidence of severe and non-surgical
postoperative complications is higher in older com-
pared to younger patients undergoing hepatic resec-
tion [55] and in patients undergoing surgery for
Klatskin Tumors [56]. Because of changes in the US
population, this age-dependence may also contribute
to increase in total CCA deaths.
In contrast to our findings in CCA, in a review of
HCC from the SEER registries and liver cancer mortality
data from the National Center for Health Statistics,
Altekruse et al. found that HCC incidence rates in SEER
registries did not significantly increase during 2007–
2010 [57] but the US liver cancer mortality rates did in-
crease [57]. These results suggest that the increased liver
cancer mortality in SEER registries may be driven by
CCA, not HCC (since ICC was combined with HCC in
the SEER registries).
The results of this study must be interpreted in the
context of some limitations. First, given that the NCHS
mortality database does not include data on comorbidi-
ties that are potential risk factors for CCA such as PSC,
we cannot quantify the contribution of these risk factors
on CCA mortality. Secondly, the mortality data was ex-
tracted from death certificates and misclassification
might occur in some cases [58, 59]. Misclassification of
the cause of death on the death certificate may occur be-
tween CCA, pancreatic cancer, gallbladder cancer and
hepatocellular cancer [60]. Another potential source of
error is that the liver is a common site of adenocarcin-
oma metastasis, and thus some secondary liver cancers
could be mistakenly over-counted as primary liver
adenocarcinoma, or ICC [57]. Conversely, CCA can be
misdiagnosed as a metastatic adenocarcinoma to the
liver rather than a primary liver cancer [15, 61].
Our study has major strengths including the use of re-
cently updated nationally representative NCHS data
through 2014 and the provision of data on both ICC and
ECC mortality. The inclusion of the entire US data mini-
mizes potential selection bias or referral bias that are
commonly encountered in institution-based studies or
age limitations of the SEER-Medicare database [25].
Furthermore, the large sample provides a unique op-
portunity to evaluate how CCA mortality varies with
age, gender, and race.
Conclusions
We found a 36 % increase in CCA mortality in 1999–
2014. ICC cases accounted for about three-quarters of
all CCA cases, in contrast to earlier reports [3], and
showed substantial increase during the study period;
ECC mortality has stayed relatively constant during the
same period. Older age, being male or Asian is associ-
ated with increased risk of CCA mortality. Among dif-
ferent race/ethnic groups, African Americans have the
highest increase in CCA mortality.
Understanding and defining the determinants of the
ethnic and gender differences informs clinical practice, as
they are relevant to developing effective strategies for the
prevention, early detection and management of CCA.
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